Which Patients Report That Their Urologists Advised Them to Forgo Initial Treatment for Prostate Cancer?

被引:3
|
作者
Radhakrishnan, Archana
Grande, David
Mitra, Nandita
Pollack, Craig Evan
机构
[1] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
ACTIVE SURVEILLANCE; DECISION-MAKING; OLDER-ADULTS; MEN CHOOSE; PROGNOSIS; RISK; MANAGEMENT; PHYSICIANS; CARE;
D O I
10.1016/j.urology.2018.01.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To examine how frequently patients report that their urologist recommended forgoing definitive treatment and assess the impact of these recommendations on treatment choice and perceived quality of cancer care. METHODS We mailed surveys to men newly diagnosed with localized prostate cancer between 2014 and 2015 (adjusted response rate of 51.3%). Men reported whether their urologist recommended forgoing definitive treatment. Using logistic regression models, we assessed patient-level predictors of receiving a recommendation to forgo definitive treatment and estimated associations of receiving this recommendation with receipt of definitive treatment and perceived quality of cancer care among men with low-risk tumors and limited life expectancies. RESULTS Nearly two-thirds (62.2%) of men with low-risk tumors and 46.4% with limited life expectancies received recommendations from their urologists to forgo definitive treatment. Among men with limited life expectancies, those with low-risk tumors were more likely to receive this recommendation compared with men with high-risk tumors (odds ratio [OR] 3.41; 95% confidence interval [CI] 2.17-5.37). Men with low-risk tumors who were recommended to forgo definitive treatment were less likely to receive definitive treatment (OR 0.48; 95% CI 0.32-0.73) but did not report lower perceived quality of care (OR 0.97; 95% CI 0.63-1.48). CONCLUSION In this population-based study, a majority of men with low-risk prostate cancer report receiving recommendations from their urologists to forgo definitive treatment. Our results suggest that urologists have a strong influence on patient treatment choice and could increase active surveillance uptake in men eligible for expectant management without patients perceiving lower quality of cancer care. (C) 2018 Elsevier Inc.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 50 条
  • [41] Urologists' Perceptions of Active Surveillance and Their Recommendations for Low-risk Prostate Cancer Patients
    Xu, Jinping
    Bock, Cathryn
    Janisse, James
    Schwartz, Kendra L.
    Triest, Jeffrey
    Cher, Michael L.
    Goodman, Michael
    UROLOGY, 2021, 155 : 83 - 89
  • [42] Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists?
    Pearcy, R.
    Waldron, D.
    O'Boyle, C.
    MacDonagh, R.
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2008, 101 (03) : 133 - 138
  • [43] How good are urologists at accurately assessing comorbid risk in patients with localised prostate cancer
    Singh, R
    O'Brien, T
    JOURNAL OF UROLOGY, 2004, 171 (04): : 34 - 34
  • [44] Role of Endorectal Prostate MRI in Patients with Initial Suspicion of Prostate Cancer
    Franiel, T.
    Vargas, A. H.
    Mazaheri, Y.
    Boehmer, S.
    Hricak, H.
    Akin, O.
    Beyersdorff, D.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2013, 185 (10): : 967 - 974
  • [45] Leukocytoclastic Vasculitis as an Initial Indicator of Prostate Cancer: A Case Report
    Barbu, Maria-Alexandra
    Ghigeanu, Miruna
    Andrei, Razvan
    Badea, Camelia G.
    AMERICAN JOURNAL OF CASE REPORTS, 2024, 25
  • [46] Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany
    Huber, Johannes
    Karschuck, Philipp
    Valdix, Johanna
    Thomas, Christian
    Koch, Rainer
    Ihrig, Andreas
    Hoelscher, Tobias
    Krones, Tanja
    Kessler, Elke
    Kliesch, Sabine
    Linne, Clemens
    Enders, Paul
    Michel, Maurice-Stephan
    Wuelfing, Christian
    Groeben, Christer
    BJU INTERNATIONAL, 2024, 134 (02) : 239 - 248
  • [47] 8 years evolution of prostate cancer (PCA) diagnostic and treatment amongst French urologists: A nationwide survey based on 717 patients
    Mongiat-Artus, P.
    Thomas, P.
    Dematons, M.
    Davin, J.
    Blum-Boisgard, C.
    Soulie, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 50 - 50
  • [48] Perceptions of Urologists About the Conversational Elements Leading to Treatment Decision-Making Among Newly Diagnosed Prostate Cancer Patients
    Prajakta Adsul
    Ricardo Wray
    Danielle Boyd
    Nancy Weaver
    Sameer Siddiqui
    Journal of Cancer Education, 2017, 32 : 580 - 588
  • [49] Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial
    Carbunaru, Samuel
    Sun, Zequn
    McCall, Cordero
    Ofori, Bernice
    Marshall, Norma
    Wang, Heidy
    Abern, Michael
    Liu, Li
    Hollowell, Courtney M. P.
    Sharifi, Roohollah
    Vidal, Patricia
    Kajdacsy-Balla, Andre
    Sekosan, Marin
    Ferrer, Karen
    Wu, Shoujin
    Gallegos, Marlene
    Gann, Peter H.
    Moreira, Daniel
    Sharp, Lisa K.
    Ferrans, Carol E.
    Murphy, Adam B.
    CANCER MEDICINE, 2023, 12 (19): : 19690 - 19700
  • [50] What urologists say they do for men with prostate cancer - Aggressive treatment for the younger man and by a specialist
    Emberton, M
    BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7179): : 276 - 276